Germany’s Ovarian Cancer diagnostics and therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of X.X% during the forecast period.
Every year in Germany approximately 9600 women develop malignant ovarian tumors. 5500 women die of ovarian cancer every year. This makes ovarian cancer the fifth most common cancer among women in Germany, after breast, colorectal, lung, and endometrial cancer, with 4.8% of cases. 70% of cases of ovarian cancer are not diagnosed until cancer has reached an advanced stage, FIGO Stages IIB to IV (spread of tumor within the pelvis or elsewhere in the abdomen). In these cases, the five-year survival rate is less than 40%. In contrast, the five-year survival rate for tumors diagnosed at early stages, FIGO Stages I to IIA, is much better: more than 80%.
Germany is expected to dominate the market for ovarian cancer diagnostics and therapeutics due to the increasing prevalence of ovarian cancer. Ovarian cancer accounts for 3.0% of all malignant tumors among women and 6.0% of all female deaths due to cancer.
Market Driving and Restraining Factors
The driving factors for the growth of the Ovarian Cancer diagnostics and therapeutics market in Germany include:
- Rising prevalence
- Persistent investment in R&D
The increasing geriatric women population and prevalence of ovarian cancer and greater use of combination therapies for the treatment of ovarian cancer can be seen as primary drivers for the growth of this market. The incidences of ovarian cancer are high in women, who are aged between 55-64 years.
Investments are also increasing in this field. Recently, 2cureX and UKE were granted a net of 810.216 EUR to adapt the IndiTreat test to ovarian cancer and to predict immunotherapy drug responses in patients suffering from colorectal cancer.
- Lack of accurate diagnosis
- Adverse effects of therapeutics
Accurate diagnosis for ovarian cancer is critical, as in most cases, cancer already begins to spread to the lymph nodes and outside of the pelvis at the time of diagnosis. Ovariancancerawareness.org reports that the five-year survival rate for ovarian cancer with early-stage 1 detection is 93% and that most new cases of ovarian cancer are diagnosed at stage 3 or later, leaving little time as well as room for an accurate diagnosis. Lack of early detection and accurate diagnosis is often since ovarian cancer symptoms are frequently overlooked, and easily confused with other conditions. Additionally, the patent expiry of key drugs is also restraining the growth of the ovarian cancer diagnostics and therapeutics market.